Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Heather Maecker, Vidya Jonnalagadda, Sunil Bhakta, Vasu Jammalamadaka & Jagath R. Junutula. (2023) Exploration of the antibody–drug conjugate clinical landscape. mAbs 15:1.
Read now
Read now
Vinay Mathew Thomas, Nishita Tripathi, Neeraj Agarwal & Umang Swami. (2022) Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Review of Anticancer Therapy 22:4, pages 335-341.
Read now
Read now
Anna R Schreiber, Michelle Andress & Jennifer R Diamond. (2021) Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Review of Anticancer Therapy 21:12, pages 1303-1311.
Read now
Read now
Kamal S Saini, Kevin Punie, Chris Twelves, Stefanella Bortini, Evandro de Azambuja, Steven Anderson, Carmen Criscitiello, Ahmad Awada & Sherene Loi. (2021) Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy 21:7, pages 945-962.
Read now
Read now
Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi, Guido Kroemer & Jonathan G. Pol. (2021) Trial watch: intratumoral immunotherapy. OncoImmunology 10:1.
Read now
Read now
Hélène Kaplon & Janice M. Reichert. (2021) Antibodies to watch in 2021. mAbs 13:1.
Read now
Read now
David M. Goldenberg & Robert M. Sharkey. (2020) Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opinion on Biological Therapy 20:8, pages 871-885.
Read now
Read now
Hélène Kaplon, Mrinalini Muralidharan, Zita Schneider & Janice M. Reichert. (2020) Antibodies to watch in 2020. mAbs 12:1.
Read now
Read now
Articles from other publishers (53)
Melanie Klee, Marie Christine Roesch, Hendrik Eggers, Philipp Ivanyi, Axel S. Merseburger & Mario Kramer. (2023) Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer. Aktuelle Urologie.
Crossref
Crossref
Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih-Wei Lin & Kyung Ho Han. (2023) Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies 12:4, pages 72.
Crossref
Crossref
Isadora Leitzke Guidotti, Alessandra Neis, Daniela Peres Martinez, Fabiana Kömmling Seixas, Karina Machado & Frederico Schmitt Kremer. (2023) Bambu and its applications in the discovery of active molecules against melanoma. Journal of Molecular Graphics and Modelling 124, pages 108564.
Crossref
Crossref
Jean Hoffman-Censits, Petros Grivas, Thomas Powles, Jessica Hawley, Karin Tyroller, Sonja Seeberger, Silke Guenther, Natalia Jacob, Keyvan Tadjalli Mehr & Noah M Hahn. (2023) The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncology.
Crossref
Crossref
Pooja Gogia, Hamza Ashraf, Sidharth Bhasin & Yiqing Xu. (2023) Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers 15:15, pages 3886.
Crossref
Crossref
Lizhou Jia, Yuhao Fu, Ning Zhang, Yang Liu, Lin Su, Haisheng Wang & Wei Zhao. (2023) Directional conjugation of Trop2 antibody to black phosphorus nanosheets for phototherapy in orthotopic gastric carcinoma. Nanomedicine: Nanotechnology, Biology and Medicine 51, pages 102687.
Crossref
Crossref
Aditya Mandapati & Kiven Erique Lukong. (2022) Triple negative breast cancer: approved treatment options and their mechanisms of action. Journal of Cancer Research and Clinical Oncology 149:7, pages 3701-3719.
Crossref
Crossref
Yu Jun Lim, Pei Sze Clarissa Lau, Shi Xuan Low, Shong Li Ng, Min Yee Ong, Huey Ming Pang, Zheng Yang Lee, Hui Yin Yow, Sharina Binti Hamzah, Renukha Sellappans & Jhi Biau Foo. (2023) How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?. Drugs and Drug Candidates 2:2, pages 377-421.
Crossref
Crossref
Nicholas C. Nicolaides, J. Bradford Kline & Luigi Grasso. (2023) NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects. PLOS ONE 18:5, pages e0285161.
Crossref
Crossref
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel & Nirav Dhanesha. (2023) Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Archives of Pharmacal Research 46:5, pages 361-388.
Crossref
Crossref
Dmytro Kobzev, Chandrashekhar Prasad, Dipak Walunj, Hodaya Gotman, Olga Semenova, Andrii Bazylevich, Leonid Patsenker & Gary Gellerman. (2023) Synthesis and biological evaluation of theranostic Trastuzumab–SN38 conjugate for Near-IR fluorescence imaging and targeted therapy of HER2+ breast cancer. European Journal of Medicinal Chemistry 252, pages 115298.
Crossref
Crossref
Christian Bailly & Gérard Vergoten. (2023) Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study. Molecules 28:4, pages 1828.
Crossref
Crossref
Manosi Banerjee & V. Devi Rajeswari. (2023) Inhibition of WNT signaling by conjugated microRNA nano-carriers: A new therapeutic approach for treating triple-negative breast cancer a perspective review. Critical Reviews in Oncology/Hematology 182, pages 103901.
Crossref
Crossref
Tylan Lucas, Joshua Chan & Neha Chopra. (2023) Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients. Oncology & Haematology 19:1, pages 1.
Crossref
Crossref
Eric Chun Hei Ho, Rong Qiu, Ellis Miller, Maria Teresa Bilotta, David FitzGerald & Antonella Antignani. (2023) Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomedicine & Pharmacotherapy 157, pages 114047.
Crossref
Crossref
Amal Ali Elkordy, Moustafa Elsayed, Sohib Bashier Al-Abdulrazag & Zeinab Moataz Zarara. 2023. Formulation of Monoclonal Antibody Therapies. Formulation of Monoclonal Antibody Therapies
287
327
.
Toshihiko Tashima. (2022) Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect. Antibodies 11:4, pages 78.
Crossref
Crossref
Mariane S Fontes, Daniel Vargas Pivato de Almeida, Clarissa Cavalin & Scott T Tagawa. (2022) Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan. OncoTargets and Therapy Volume 15, pages 1531-1542.
Crossref
Crossref
Xiaotao Qian, Yongxin Zhao, Tengyue Zhang & Pingsheng Fan. (2022) Downregulation of MACC1 facilitates the reversal effect of verapamil on the chemoresistance to active metabolite of irinotecan in human colon cancer cells. Heliyon 8:11, pages e11294.
Crossref
Crossref
Shuanghe Li, Chongyang Bao, Lingli Huang & Ji-Fu Wei. (2022) Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective. Journal of Clinical Medicine 11:20, pages 6021.
Crossref
Crossref
Sindhusha Veeraballi, Zaineb Khawar, Hafiz Muhammad Aslam & Mahvish Muzaffar. (2022) Role of sacituzumab govitecan in solid tumors. Journal of Oncology Pharmacy Practice 28:7, pages 1617-1623.
Crossref
Crossref
David C. Swinney. (2022) Why medicines work. Pharmacology & Therapeutics 238, pages 108175.
Crossref
Crossref
Qiuping Qin & Likun Gong. (2022) Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27:19, pages 6299.
Crossref
Crossref
Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, See Phan & Javier Cortés. (2022) Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment 195:2, pages 127-139.
Crossref
Crossref
Seungmin Han, Kwang Suk Lim, Brody J. Blackburn, Jina Yun, Charles W. Putnam, David A. Bull & Young-Wook Won. (2022) The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates. Pharmaceutics 14:8, pages 1707.
Crossref
Crossref
Beverly A. Teicher & Joel Morris. (2022) Antibody-drug Conjugate Targets, Drugs, and Linkers. Current Cancer Drug Targets 22:6, pages 463-529.
Crossref
Crossref
Paul J. Carter & Arvind Rajpal. (2022) Designing antibodies as therapeutics. Cell 185:15, pages 2789-2805.
Crossref
Crossref
Fei Wu, Thomas C. Gardinier, Melik Z. Turker, Feng Chen, Pei-Ming Chen, Aranapakam M. Venkatesan, Vaibhav Patel, Gregory P. Adams, Michelle S. Bradbury, Ulrich B. Wiesner, Geno Germano & Kai Ma. (2022) Molecular Engineering of Surface Functional Groups Enabling Clinical Translation of Nanoparticle–Drug Conjugates. Chemistry of Materials 34:12, pages 5344-5355.
Crossref
Crossref
Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao, Hiroaki Fushimi, Kotoe Katayama, Seiya Imoto, Kazuhiro Yoshimura, Ryoichi Imamura, Hirotsugu Uemura & Norio Nonomura. (2022) Trop-2 in Upper Tract Urothelial Carcinoma. Current Oncology 29:6, pages 3911-3921.
Crossref
Crossref
Siddharth Menon, Sagun Parakh, Andrew M. Scott & Hui K. Gan. (2022) Antibody-drug conjugates: beyond current approvals and potential future strategies. Exploration of Targeted Anti-tumor Therapy, pages 252-277.
Crossref
Crossref
Yu Fan, Qinhan Li, Qi Shen, Zhifu Liu, Zhenan Zhang, Shuai Hu, Wei Yu, Zhisong He, Qun He & Qian Zhang. (2022) Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. Frontiers in Oncology 12.
Crossref
Crossref
Kirollos S Hanna, Samantha Larson, Jenny Nguyen, Jenna Boudreau, Jennifer Bulin & Mallory Rolf. (2022) The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. American Journal of Health-System Pharmacy 79:8, pages 629-635.
Crossref
Crossref
Jung Hoon Kim & In Ho Chang. (2022) A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and Clinical Urology 63:4, pages 373.
Crossref
Crossref
David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan & Thomas M. Cardillo. (2022) Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter. Molecular Cancer Therapeutics 21:1, pages 237-237.
Crossref
Crossref
Xinling Zhang, Andrew C Huang, Fahai Chen, Hu Chen, Lele Li, Nana Kong, Wenting Luo & Jianmin Fang. (2022) Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics 5:1, pages 18-29.
Crossref
Crossref
Md Abdus Subhan & Vladimir P. Torchilin. (2021) Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 169, pages 241-255.
Crossref
Crossref
Sophie Wucherpfennig, Michael Rose, Angela Maurer, Maria Angela Cassataro, Lancelot Seillier, Ronja Morsch, Ehab Hammad, Philipp Heinrich Baldia, Thorsten H. Ecke, Thomas-Alexander Vögeli, Ruth Knüchel & Nadine T. Gaisa. (2021) Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. International Journal of Molecular Sciences 22:21, pages 11547.
Crossref
Crossref
Cristina Martín-Sabroso, Irene Lozza, Ana Isabel Torres-Suárez & Ana Isabel Fraguas-Sánchez. (2021) Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics 13:10, pages 1705.
Crossref
Crossref
David Chiu, Lucy Pan, Lindsay Fay, Catherine Eakin & John Valliere-Douglass. (2021) Structural characterization of a monomethylauristatin-E based ADC that contains 8 drugs conjugated at interchain cysteine residues. Journal of Pharmaceutical and Biomedical Analysis 205, pages 114309.
Crossref
Crossref
Laura M. Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle Blouin, Colin Weekes, Hope Rugo, Beverly Moy & Aditya Bardia. (2021) Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. The Oncologist 26:10, pages 827-834.
Crossref
Crossref
Manar Hammood, Andrew Craig & Jeffrey Leyton. (2021) Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development. Pharmaceuticals 14:7, pages 674.
Crossref
Crossref
John M. Seligson, Alexandra M. Patron, Michael J. Berger, R. Donald Harvey & Nathan D. Seligson. (2020) Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Annals of Pharmacotherapy 55:7, pages 921-931.
Crossref
Crossref
Robert G. Strickley & William J. Lambert. (2021) A review of Formulations of Commercially Available Antibodies. Journal of Pharmaceutical Sciences 110:7, pages 2590-2608.e56.
Crossref
Crossref
A. Bardia, W.A. Messersmith, E.A. Kio, J.D. Berlin, L. Vahdat, G.A. Masters, R. Moroose, A.D. Santin, K. Kalinsky, V. Picozzi, J. O'Shaughnessy, J.E. Gray, T. Komiya, J.M. Lang, J.C. Chang, A. Starodub, D.M. Goldenberg, R.M. Sharkey, P. Maliakal, Q. Hong, W.A. Wegener, T. Goswami & A.J. Ocean. (2021) Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals of Oncology 32:6, pages 746-756.
Crossref
Crossref
Qingyan Ruan, Gopal Patel, Jingyi Wang, Enhui Luo, Wei Zhou, Elwira Sieniawska, Xiaolong Hao & Guoyin Kai. (2021) Current advances of endophytes as a platform for production of anti-cancer drug camptothecin. Food and Chemical Toxicology 151, pages 112113.
Crossref
Crossref
Aditya BardiaSara A. HurvitzSara M. TolaneyDelphine LoiratKevin PunieMafalda OliveiraAdam BrufskySagar D. SardesaiKevin KalinskyAmelia B. ZelnakRobert WeaverTiffany TrainaFlorence DalencPhilippe AftimosFilipa LynceSami DiabJavier CortésJoyce O’ShaughnessyVéronique DiérasCristiano FerrarioPeter SchmidLisa A. CareyLuca GianniMartine J. PiccartSibylle LoiblDavid M. GoldenbergQuan HongMartin S. OlivoLoretta M. ItriHope S. Rugo. (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine 384:16, pages 1529-1541.
Crossref
Crossref
Shino Manabe & Kenji Hirose. (2021) Chemistry in ADC Development抗体－薬物複合体（ADC）に活用された化学. Drug Delivery System 36:1, pages 28-39.
Crossref
Crossref
K. Kalinsky, J.R. Diamond, L.T. Vahdat, S.M. Tolaney, D. Juric, J. O'Shaughnessy, R.L. Moroose, I.A. Mayer, V.G. Abramson, D.M. Goldenberg, R.M. Sharkey, P. Maliakal, Q. Hong, T. Goswami, W.A. Wegener & A. Bardia. (2020) Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology 31:12, pages 1709-1718.
Crossref
Crossref
Sára Lenárt, Peter Lenárt, Jan Šmarda, Ján Remšík, Karel Souček & Petr Beneš. (2020) Trop2: Jack of All Trades, Master of None. Cancers 12:11, pages 3328.
Crossref
Crossref
Stefania Cocco, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira di Gioia, Marina Licenziato & Michelino de Laurentiis. (2020) Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences 21:13, pages 4579.
Crossref
Crossref
Valentina Boni, Manish R. Sharma & Amita Patnaik. (2020) The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. American Society of Clinical Oncology Educational Book:40, pages e58-e74.
Crossref
Crossref
Christian Bailly. (2019) Irinotecan: 25 years of cancer treatment. Pharmacological Research 148, pages 104398.
Crossref
Crossref
Mary-Ann Bjornsti & Scott H. Kaufmann. (2019) Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Research 8, pages 1704.
Crossref
Crossref